盐酸伊普可泮胶囊 | China Drugs ListIptacopan hydrochloride capsules | China Drugs List

本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。

企业: Novartis PharmaSchweiz AGNovartis Pharma Schweiz AG
药品类型: 化学药Chemical medicine
治疗领域: 非恶性血液疾病Non-malignant blood disorders
公开来源记录的适应症: 本品适用于治疗: 1阵发性睡眠性血红蛋白尿症(PNH)成人患者。 2C3肾小球病(C3G)成人患者,以降低蛋白尿。【中国2025年9月新增】用于降低有疾病快速进展风险的原发性免疫球蛋白A肾病（IgA肾病）成人患者的蛋白尿水平，为中国附条件批准。美国2026年7月“减缓IgAN肾功能下降”常规批准未直接迁移为中国适应症。1. Treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). 2. Treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria. Added in China in September 2025: Reduction of proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression; this Chinese indication has conditional approval. The July 2026 US regular approval for slowing kidney function decline in IgA nephropathy has not been treated as an approved Chinese indication.
适应症来源与口径: 来源日期： 2025, 2026, 2026-07-24. 适应症转录自国家医保局公开的企业申报资料；不代表已核实完整的现行说明书。新增适应症可能由较新的公告或申报资料支持，而非旧版完整说明书；请查看适应症来源。Source date(s): 2025, 2026, 2026-07-24. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
说明书信息局限: 已取得完整官方药品说明书。现有完整说明书来自海外辖区；尚未取得完整的中国现行说明书。中国适应症另由中国来源支持。Complete official prescribing information obtained. The available full label is from an overseas jurisdiction; a complete current Chinese label remains unavailable. Chinese indications are supported separately by Chinese sources.
中国可获得性状态: 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
海外状态: 日本, 英国: 已取得当地获批／上市公告及官方价格来源。每条价格记录注明适应症与日期；未全面核查其他市场。Japan, United Kingdom: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
医保分类: 已纳入国家医保（乙类）Included in national insurance (Category B)
医保版本: 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
医保限制: 限：1.阵发性睡眠性血红蛋白尿症(PNH)成人患者；2.C3肾小球病(C3G)成人患者。Limited to: 1. Adults with PNH. 2. Adults with C3G.
医保期限: 2026-01-01 至 2026-12-312026-01-01 to 2026-12-31
医保核查说明: 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

来源

打开交互详情、公开价格与讨论